214 related articles for article (PubMed ID: 32040979)
1. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R).
Schmitt A; Günther R; Mauss S; Boeker KHW; Buggisch P; Hillenbrand H; John C; Klinker H; Pathil A; Simon KG; Serfert Y; Niederau C; Vermehren J; Wedemeyer H; Sarrazin C
Z Gastroenterol; 2020 Apr; 58(4):341-351. PubMed ID: 32040979
[TBL] [Abstract][Full Text] [Related]
2. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.
Graf C; D'Ambrosio R; Degasperi E; Paolucci S; Llaneras J; Vermehren J; Dultz G; Peiffer KH; Finkelmeier F; Herrmann E; Zeuzem S; Buti M; Lampertico P; Dietz J; Sarrazin C
JHEP Rep; 2024 Mar; 6(3):100994. PubMed ID: 38357421
[TBL] [Abstract][Full Text] [Related]
4. A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
El-Kassas M; Emadeldeen M; Hassany M; Esmat G; Gomaa AA; El-Raey F; Congly SE; Liu H; Lee SS
J Hepatol; 2023 Aug; 79(2):314-320. PubMed ID: 37088312
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Devan P; Tiong KLA; Neo JE; Mohan BP; Wijarnpreecha K; Tam YCS; Coppola N; Preda CM; Wong YJ
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515176
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
7. Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
Sarrazin C; Buggisch P; Mauss S; Müller T; Zimmermann T; Klinker H; Pathil-Warth A; Schlag M; Nalpas C; Wegner S; Lonjon-Domanec I; Simon KG
Z Gastroenterol; 2019 May; 57(5):584-592. PubMed ID: 31083746
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Vermehren J; Serfert Y; Cornberg M; Stoehr A; Klinker H; Simon KG; Teuber G; Deterding K; Schulze Zur Wiesch J; Jung MC; Manns MP; Zeuzem S; Wedemeyer H; Sarrazin C
Z Gastroenterol; 2020 Sep; 58(9):841-846. PubMed ID: 32947629
[TBL] [Abstract][Full Text] [Related]
9. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Da BL; Lourdusamy V; Kushner T; Dieterich D; Saberi B
Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):859-861. PubMed ID: 32541241
[TBL] [Abstract][Full Text] [Related]
11. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
13. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP
PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
15. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
16. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
Sikavi C; Najarian L; Saab S
Dig Dis Sci; 2018 Nov; 63(11):2829-2839. PubMed ID: 30094623
[TBL] [Abstract][Full Text] [Related]
17. Treatment and re-treatment results of HCV patients in the DAA era.
Piecha F; Gänßler JM; Ozga AK; Wehmeyer MH; Dietz J; Kluwe J; Laschtowitz A; von Felden J; Sterneck M; Jordan S; Pischke S; Lohse AW; Schulze Zur Wiesch J
PLoS One; 2020; 15(5):e0232773. PubMed ID: 32369527
[TBL] [Abstract][Full Text] [Related]
18. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
[TBL] [Abstract][Full Text] [Related]
19. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
[TBL] [Abstract][Full Text] [Related]
20. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.
Hartman J; Bichoupan K; Patel N; Chekuri S; Harty A; Dieterich D; Perumalswami P; Branch AD
World J Gastroenterol; 2015 Nov; 21(43):12430-8. PubMed ID: 26604650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
